CRISPR Therapeutics to raise ~$280M via sale of 3.9M common shares at $71.50/share

CRISPR Therapeutics AG

Issues 3,916,082 common shares at $71.50 per share to institutional investors.
Gross proceeds of approximately $280 million; offering not underwritten, direct to investors.
Shares offered under existing shelf registration statement (Form S-3, filed July 2021).
Closing expected within ten trading days after February 13, 2024.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

CRISPR Therapeutics AG entered into Investment Agreement with certain institutional investors valued at $280 million (effective 2024-02-13).

Action: entry
Agreement: equity purchase
Counterparty: certain institutional investors
Value: $280 million
Effective: 2024-02-13

Exact text from the filing

On February 13, 2024, CRISPR Therapeutics AG (the “Company”) entered into an investment agreement (the “Investment Agreement”) with certain institutional investors relating to the issuance of 3,916,082 shares of the Company’s common shares, par value of CHF 0.03 per share (the “Common Shares”), to such investors (the “Offering”).

View on SEC.gov

Browse all material agreements →

CRISPR Therapeutics AG filing history →

Source: SEC EDGAR

accession 0001193125-24-033973

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.